FDA Replies To AstraZeneca Citizen Petitions On Quetiapine Product Labeling

AstraZeneca To Buy Pearl Therapeutics For Up To $1.15 Bln - Quick Facts

AstraZeneca Decides Not To Proceed With Regulatory Filings For Fostamatinib

AstraZeneca To Buy Omthera Pharma For About $323 Mln

AstraZeneca To Buy Omthera Pharma - Quick Facts

Trade AZN now with

3/9/2012 2:53 AM ET

AstraZeneca Plc (AZN: Quote,AZN.L) announced that on March 7, 2012, the Food and Drug Administration, or FDA, denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

The company stated that it is evaluating the FDA's decision and reasoning.

Click here to receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 75 Articles

Editors Pick

Australia Leading Index Suggests Above-Trend Growth

A leading indicator of Australian economic activity continued to signal above-trend growth for the economy in the coming quarters, a report from Westpac and Melbourne Institute showed Wednesday. The annualized growth rate of the leading index, which indicates the likely pace of economic activity three to nine months into the future, was 5.4 percent in April, comfortably above its long term trend.

Adobe Profit Tops Estimate

Publishing and design software maker Adobe Systems Inc. said Tuesday after the markets closed that its second quarter profit fell 66% from last year, hurt by lower revenue as well as higher costs and expenses. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations and its quarterly revenue was in line with analysts' forecast.

Stocks Show Strong Upward Move Ahead Of Fed Announcement - U.S. Commentary

Stocks showed a strong upward move over the course of the trading day on Tuesday, adding to the gains posted in the previous session. The rally came even as traders expressed some uncertainty ahead of tomorrow's Federal Reserve announcement. The major averages gave back some ground going into the close but remained firmly in positive territory.